A phase 2 open-label study of the safety and efficacy of weekly dosing of ATL1102 in patients with non-ambulatory Duchenne muscular dystrophy and pharmacology in mdx mice

• Ian R. Woodcock,
• George Tachas,
• Nuket Desem,
• Peter J. Houweling,
• Michael Kean,
• Jaiman Emmanuel,
• Rachel Kennedy,
• Kate Carroll,
• Katy de Valle,
• Justine Adams,
• Shireen R. Lamandé,
• Chantal Coles,
• Chrystal Tiong,
• Matthew Burton,
• Daniella Villano,
• Peter Button,
• Jean-Yves Hogrel,
• Sarah Catling-Seyffer,
• Monique M. Ryan,
• Martin B. Delatycki,
• Eppie M. Yiu

Affiliations

Ian R. Woodcock

George Tachas

Nuket Desem

Peter J. Houweling

Michael Kean

Jaiman Emmanuel

Rachel Kennedy

Kate Carroll

Katy de Valle

Justine Adams

Shireen R. Lamandé

Chantal Coles

Chrystal Tiong

Matthew Burton

Daniella Villano

Peter Button

Jean-Yves Hogrel

Sarah Catling-Seyffer

Monique M. Ryan

Martin B. Delatycki

Eppie M. Yiu